Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |
| postcoital_contraception [2026/09/21 11:27] – [options:] gary1 | postcoital_contraception [2026/09/21 11:27] (current) – [options:] gary1 |
|---|
| |
| ===low-dose or mid-dose mifepristone === | ===low-dose or mid-dose mifepristone === |
| *a Cochrane review of studies in 2026(([[https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016275/full]])) appear to show mid-dose mifepristone (25-50 mg) prevented more pregnancies and were associated with fewer overall side effects (nausea and vomiting) than levonorgestrel but a higher likelihood of delayed menstruation and this could cause stress with patients thinking they may be pregnant - low dose (< 25mg) reduces the risk of early menses after treatment but slightly increases the risk of delayed menses compare to levonorgestrel but less risk than with mid-dose mifepristone | *a Cochrane review of studies in 2026(([[https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016275/full]])) appear to show mid-dose mifepristone (25-50 mg) prevented more pregnancies and were associated with fewer overall side effects (nausea and vomiting) than levonorgestrel but a **higher likelihood of delayed menstruation and this could cause stress with patients thinking they may be pregnant** - low dose (< 25mg) reduces the risk of early menses after treatment but slightly increases the risk of delayed menses compare to levonorgestrel but less risk than with mid-dose mifepristone |
| *not yet licensed in Australia for this purpose | *not yet licensed in Australia for this purpose |
